Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temelimab Extension in Relapsing Multiple Sclerosis
NCT05049161Phase 2Terminated
- Sponsor
- GeNeuro
- Start
- Aug 2021
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of temelimab in multiple sclerosis (MS), sponsored by GeNeuro. Started Aug 2021; status: terminated.
02
Drugs
temelimab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05049161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05049161.